Company Overview - MacroGenics has been focused on next-generation antibody therapeutics for cancer treatment for over 20 years [2] - The company leverages three core modalities to drive its proprietary pipeline, including an ADC portfolio that utilizes third-party drug linker chemistries from Synaffix, now part of Lonza [3] Product Pipeline - MacroGenics has three disclosed ADC programs in its current portfolio [3] - The company has a broad partnership with Gilead that includes three T cell-related constructs, with one clinical program targeting CD123 and CD3, and two undisclosed preclinical programs [4]